Description
Designs for Health – AU
- New double strength formula
- Contains Clinically Studied Levagen+™
- LipiSperse® technology to enhance water solubility and bioavailability/absorption.
- With 30mg of quercetin per capsule
- Natural pain relief
- Relieves mild Neuralgia
- Vegan Friendly
EDUCATION
Chronic pain is defined as the persistent presence of mild to severe pain for at least 3-6 months beyond the usual duration that healing is generally expected following an illness or injury. It is highly prevalent, affecting at least 19-24% of Australians aged over 45, (particularly females and older individuals), and 38-43% of people worldwide, with significant adverse influences on the quality of life and productivity of affected individuals. Chronic pain is complex in regards to its’ aetiology, pathophysiology and mechanistic classification, and consequently, its effective therapeutic management/treatment without the occurrence of side effects is an ongoing clinical challenge.
Lipisperse™ Technology
Enabling the therapeutic potential of Levagen+™ Palmidrol (Palmitoylethanolamide [PEA]) requires enhanced absorption due to the suboptimal water-soluble properties of this lipid group. LipiSperse®, a mixture of surfactants, polar lipids and solvents, is a novel delivery system scientifically formulated to increase the dispersion of lipophilic agents in aqueous environments. By preventing agglomeration in the gastrointestinal tract, LipiSperse® increases the surface area of PEA resulting in enhanced absorption and significantly increased plasma PEA concentrations compared with standard PEA formulations.
Palmidrol (PEA)
PEA, an endogenous acyl ethanonolamide, is a saturated fatty acid derived from palmitic acid that is synthesized within the lipid bilayer of cell membranes in various body tissues as required in response to stress, injury or pain. Elevated levels of PEA have been observed systemically and locally in chronic pain conditions and during tissue injury and inflammation processes.
